About SLE
SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.
Read more details at: http://www.bigmarketresearch.com/global-systemic-lupus-erythematosus-sle-drugs-2015-2019-market
Analysts forecast the Global SLE Drugs market to grow at a CAGR of 22.41 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Global SLE Drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of SLE that are available in the market.
Global SLE Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA; it covers the Global SLE Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Anthera Pharmaceuticals
• BMS
• GSK
• ImmuPharma
• Merck Serono
• UCB
Other Prominent Vendors
• Amgen
• HGS
• Immunomedics
• Johnson and Johnson
• MedImmune
• Sanofi
• Teva Pharmaceutical Industries
Market Driver
• High Prevalence of Autoimmune Disease
• For a full, detailed list, view our report
Market Challenge
• Complex Etiology
• For a full, detailed list, view our report
Market Trend
•...